Disease modification in OA — will we ever get there?

Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

Abstract

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • University of Southern Denmark
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Reumatologi och inflammation
Originalspråkengelska
TidskriftNature Reviews Rheumatology
StatusPublished - 2019 feb 7
PublikationskategoriForskning
Peer review utfördJa